

**GF/B45/EDP14**      **Approval of the Secretariat's Recommendation on Funding from the COVID-19 Response Mechanism (Indonesia and Nigeria)**

Approved on 13 August 2021

The Board:

1. Notes its decision in GF/B44/EDP18, which requires the Secretariat to recommend to the Board, for its approval, any COVID-19 Response Mechanism ("C19RM") awards exceeding US\$35 million, as measured in aggregate by country (not including any funding awarded for COVID-19 commodities through fast-track investments or C19RM funding awarded in 2020);
2. Approves the funding recommended for each country, as listed in Table 1 of GF/B44/ER13; and
3. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country among its constituent grants in accordance with the previously approved principles under GF/B44/EDP18.

This decision does not raise new, material budgetary implications for operating expenses

**Table 1: Secretariat's Recommendation on Funding from C19RM<sup>1</sup>**

Please note that each country name is [linked](#) to the extranet site where relevant supporting documents are available for review.

Country/ Multicountry	Grant name	Currency	C19RM 2020 carry-over amount <sup>2</sup>	Previously approved C19RM 2021 award <sup>3</sup>	C19RM 2021 recommende d amount for Board approval	Total C19RM 2021 funding	% of 2020-2022 allocation	Total C19RM 2021 funding plus C19RM 2020 carry- over	C19RM Unfunded Demand
<a href="#">Indonesia</a>	IDN-H-MOH	US\$	0	2,834,052	13,512,370	65,811,909	22.4%	65,811,909	5,456,433
	IDN-H-SPIRITI	US\$	0	10,588	642,567				
	IDN-M-MOH	US\$	0	783,523	7,997,386				
	IDN-M- PERDHAK	US\$	0	1,230,883	9,463,443				
	IDN-T-MOH	US\$	0	10,457,580	17,392,626				
	IDN-T-PBSTPI	US\$	0	0	1,486,891				
<a href="#">Nigeria</a>	NGA-S-NACA	US\$	22,662,855	50,083,594	172,565,824	222,649,418	25.0%	246,882,212	88,928,456
	NGA-T-LSMOH	US\$	1,569,939	0	0				

<sup>1</sup> The C19RM Investment Committee recommends C19RM full funding requests awards of more than US\$35 million to the Global Fund Board for approval. This amount, measured in aggregate per country, does not include any funding awarded through the C19RM fast-track process or through C19RM in 2020. The C19RM Investment Committee may also recommend awards under US\$35 million to the Global Fund Board for approval where it determines that the non-health product components of an award are of a nature and scale which raise significant concerns about risk and complexity.

<sup>2</sup> Estimated funds remaining from C19RM 2020 awards previously approved by the C19RM Investment Committee and carried over to this new award.

<sup>3</sup> This includes Secretariat approved fast-track and full funding awards, as well as awards previously approved by the Board.